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Fetal growth restriction (FGR) is a common pregnancy complication that affects up to
5% of pregnancies worldwide. Recent studies demonstrate that Vitamin D deficiency
is implicated in reduced fetal growth, which may be rescued by supplementation of
Vitamin D. Despite this, the pathway(s) by which Vitamin Dmodulate fetal growth remains
to be investigated. Our own studies demonstrate that the Vitamin D receptor (VDR)
is significantly decreased in placentae from human pregnancies complicated by FGR
and contributes to abnormal placental trophoblast apoptosis and differentiation and
regulation of cell-cycle genes in vitro. Thus, Vitamin D signaling is important for normal
placental function and fetal growth. This review discusses the association of Vitamin D
with fetal growth, the function of Vitamin D and its receptor in pregnancy, as well as
the functional significance of a placental source of Vitamin D in FGR. Additionally, we
propose that for Vitamin D to be clinically effective to prevent and manage FGR, the
molecular mechanisms of Vitamin D and its receptor in modulating fetal growth requires
further investigation.
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INTRODUCTION
Fetal growth restriction (FGR) is defined as the failure of a fetus to reach its full growth potential
for its gestational age, and complicates up to 5% of all pregnancies (McIntire et al., 1999; Scifres
and Nelson, 2009). A low birth weight, accompanied by additional pathologies such as asymmetric
growth and reduced amniotic fluid index, allows clinicians to distinguish FGR cases from infants
who are born small for gestational age, but are otherwise healthy. FGR is associated with increased
risks of perinatal complications such as prematurity (Gardosi et al., 1998) and stillbirth (Kramer
et al., 1990; Cnattingius et al., 1998; Gardosi et al., 1998; Froen et al., 2004), in addition to an
increased risk of mortality (Kramer et al., 1990; McIntire et al., 1999). Long-term adverse outcomes
include impaired neuropsychological development (Taylor and Howie, 1989; Frisk et al., 2002),
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reduced intelligence quotients (Goldenberg et al., 1996; Matte
et al., 2001) and poor metabolic health with greater risk of
chronic adulthood diseases including hypertension, ischemic
heart disease, and diabetes (Barker, 1990; Godfrey and Barker,
2001). Thus, FGR has potential lifelong consequences for an
infant (Ponsonby et al., 2010).
While there are several factors attributed to the causes of FGR,
including fetal chromosomal abnormalities, placental infarcts,
maternal tobacco smoking, and poor nutrition; for the majority
of cases, ∼70%, there is no known cause (Sankaran and Kyle,
2009). Idiopathic FGR is often associated with uteroplacental
vascular insufficiency, whereby there is abnormal placental
development and function, which leads to impaired vascular flow
to the placenta (Robinson et al., 2000). Sampling of the umbilical
cord blood from growth restricted infants shows chronic and
inadequate transplacental oxygenation from mother to child
(Ghidini, 1996). Clinical features of poor placental perfusion
are abnormal umbilical artery Doppler velocimetry such as
decreased, absent or even reverse diastolic flow (Salafia et al.,
1997), oligohydramnios (Harman, 2008), and asymmetric fetal
growth (Vik et al., 1997). The molecular mechanisms underlying
such uteroplacental insufficiency remain largely unknown.
VITAMIN D METABOLISM, TRANSPORT,
AND BIOAVAILABILITY
Vitamin D exists in two forms; Vitamin D3 and Vitamin D2, both
of which have very similar structures. Vitamin D3 contributes
to 95% of the Vitamin D levels in the human circulation
(Holick, 2003). The major source of Vitamin D in humans is the
cutaneous synthesis of pre-Vitamin D3, which is derived from
7-dehydrocholesterol through exposure to ultraviolet radiation
(Holick, 2007). Vitamin D3 varies with the level of sunlight
exposure and is extremely susceptible to seasonal changes
(Holick, 2007). Vitamin D stores can be built up during summer
months and utilized as serum levels drop during the winter
(Holick, 1994; Heaney, 2005; Heaney et al., 2005). In contrast,
Vitamin D2, which is a third as potent as Vitamin D3, is found in
some plants, dietary supplements, and multi-vitamins (Norman,
2012). Major dietary sources of Vitamin D include oily fish,
fortified margarines and some breakfast cereals, while smaller
amounts are present in red meat and egg yolk (Atkinson, 2011),
although these contribute only small amounts compared to
endogenous synthesis.
Vitamin D (either D2 or D3) made in the skin or ingested in
the diet can be stored in and then released from fat cells. Both
forms of Vitamin D are biologically inactive and must undergo
two sequential hydroxylations by mitochondrial enzymes known
as 25-hydroxylase (CYP2R1) and 1-α-hydroxylase (CYP27B1)
to become calcidiol [25(OH)D] and calcitriol [1,25(OH)2D]
respectively (Holick, 2007). Vitamin D in the circulation binds
to the Vitamin D–binding protein, which then transports it to
the liver, where it is converted by CYP24A1, a 24-hydroxylase
mitochondrial cytochrome p450 enzyme, to a pre-Vitamin D,
25(OH)D. This form of Vitamin D is biologically inactive
and must be converted in the kidneys by 1α- hydroxylase (1-
OHase) to the biologically active form, 1,25-dihydroxyVitamin
D[1,25(OH)2D]. Serum phosphorus, calcium, fibroblast growth
factor 23 (FGF-23), and other factors alter the renal production
of 1,25(OH)2D. 1,25(OH)2D increases the expression of 25-
hydroxyvitamin D by Vitamin D-24- hydroxylase (24-OHase) to
catabolize 1,25(OH)2D to the water-soluble, biologically inactive
calcitroic acid, which is then excreted in the bile. The CYP24A1
hydroxylase enzyme also converts substrates into inactive end
products, including 1,24,25-trihydroxyvitamin D and 24,25-
dihydroxyvitamin D (Omdahl et al., 2002). As a protective
mechanism to prevent Vitamin D intoxication (due to excessive
exposure to sunlight), pre-Vitamin D3 and Vitamin D3 can
be converted to inactive products by solar ultraviolet radiation
(Holick, 2007).
VITAMIN D RECEPTOR (VDR)
Vitamin D has limited effects on most target cells and
its biological activity often correlates with free Vitamin D
concentration, where the unbound form of 1,25(OH)2D diffuses
across the plasmamembrane and binds to its high affinity nuclear
receptor, VDR. VDR can mediate both non-transcriptional
and transcriptional effects. In the transcriptional pathway,
1,25(OH)2D bound VDR heterodimerises with a partner
receptor, retinoid X receptor (RXR). This VDR-RXR complex
regulates the transcription of Vitamin D target genes by binding
with high affinity Vitamin D response element (VDRE) located
in the promoter region, resulting in a cascade of cellular events
(Avila et al., 2007). On the other hand, the non-transcriptional
pathway involves calcitriol-VDR complex binding with caveolae
stimulating numerous signaling cascades, such as protein kinase
C and mitogen-activated protein kinase (Shin et al., 2010).
These signaling cascades play a pivotal role in regulating cellular
functions such as proliferation, differentiation, invasion, and
apoptosis hence highlighting the modulatory effects of Vitamin
D. VDR allelic variants and altered VDR expressions are
associated with a number of health concerns including prostate
cancer (Ingles et al., 1997), breast cancer (Whitfield et al., 2001),
and sarcoidosis (Niimi et al., 1999), but the role of VDR and
Vitamin D signaling in pregnancy is poorly understood.
VITAMIN D HOMEOSTASIS IN
PREGNANCY
Vitamin D is a pleiotropic secosteroid hormone, which is
pivotal for the maintenance of calcium homeostasis, bone
mineralization, immune regulation, cellular proliferation, and
prevention of disorders (Norman, 2012). Vitamin D status
is reflected by the circulating 25(OH)D concentrations,
for which the normal range is defined to be between
∼ 32ng/mL and ∼ 80ng/mL, with values below ∼32 ng/mL
is defined as Vitamin D deficiency (Holick, 2007).
Emerging evidence in observational studies indicate that a low
circulating 25(OH)D concentration is associated with increased
risks of infertility, preeclampsia and gestational diabetes mellitus.
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Vitamin D deficiency has also been linked to early on-set
preeclampsia associated with FGR (Robinson et al., 2010). A
number of large observational studies report a significant link
between low maternal serum Vitamin D and an increased risk
of preeclampsia (Bodnar et al., 2007; Fischer et al., 2007; Haugen
et al., 2009; Baker et al., 2010; Robinson et al., 2010; Yu et al.,
2013). Bodnar et al. (2007) conducted a nested case control study
following pregnant women from less than 16 weeks gestation
to delivery and correlated maternal Vitamin D status with the
risk of developing preeclampsia, finding that serum 25(OH)D
levels early in pregnancy were significantly lower in women who
went on to develop preeclampsia than in controls (Bodnar et al.,
2007). Similarly, Haugen et al. (2009) collected data from 23,423
pregnant women in Norway and calculated the Vitamin D intake
throughout pregnancy via questionnaires, finding that women
who took Vitamin D supplementation were 27% less likely to
develop preeclampsia than those who took no supplementation
(Haugen et al., 2009). The results of these studies were supported
by Baker et al. (2010) who, after conducting a nested case control
study of 3992 pregnant women, found that maternal Vitamin D
deficiency was found to be associated with an increased risk (OR
5.41) of severe preeclampsia (Baker et al., 2010).
In contrast to these studies, Yu et al. (2013) conducted a
case-control study of 150 singleton pregnancies who developed
preeclampsia and 100 unaffected controls and investigated if
Vitamin D levels at 11–13 weeks gestation were altered in those
who developed preeclampsia (Yu et al., 2013). The results of this
study indicated that first trimester serumVitaminD levels are not
different for pregnancies that subsequently developed late on-set
preeclampsia. As such, it was proposed that identifying specific
cases of preeclampsia based on severity and gestation may lead
to a better understanding of the pathogenesis. This is supported
by a number of studies which have found an association between
maternal Vitamin D and early onset and severe preeclampsia, but
no association between maternal Vitamin D and preeclampsia
risk overall was observed. Robinson et al. reported significantly
decreased maternal Vitamin D in early onset severe preeclampsia
associated with FGR compared to healthy controls (Robinson
et al., 2010). Similarly Bodnar et al. found an association
between maternal Vitamin D and cases of severe preeclampsia
(Bodnar et al., 2014). Low Vitamin D levels have been associated
with vascular endothelial cell inflammatory response, increased
cytokine mediated suppression of vascular endothelial function
and reduced endothelial Vitamin D receptor (VDR) expression
(Tarcin et al., 2009; Wei et al., 2013).
THE ROLE OF THE PLACENTA IN VITAMIN
D METABOLISM
While the specific mechanisms of Vitamin D during pregnancy
are not fully understood, Vitamin D undeniably plays an
important role in implantation, placentation, and maintenance
of a healthy pregnancy. The placenta, which lies between mother
and fetus, is the primary site of waste removal, nutrient and
gas exchange, and together with the decidua has an important
role in Vitamin D metabolism during pregnancy. During human
pregnancy, the conversion of 25(OH)D to 1,25(OH)2D is
increased in the placenta as well as the maternal kidney and
decidua (Weisman et al., 1979). The maternal decidua makes
1,25(OH)2D and 24,25(OH)2D while the placenta synthesizes
24,25(OH)2D (Weisman et al., 1976). The inactive 24,25(OH)2D
synthesized by the placenta accumulates in fetal bone and
significantly contributes to skeletal ossification (Weisman et al.,
1976). DNA methylation, histone modifications and non-coding
RNAs can also affect gene expression in the placenta. Thus,
altered genomic imprinting of VDR has effects on both fetal
and placental development (Nelissen et al., 2011). However, very
little is known about the impact of external (environmental)
influences on the Vitamin D system in pregnancy, or the possible
genetic and epigenetic variations that might affect Vitamin D
homeostasis at the feto-maternal interface and their effects on
overall feto-placental growth and development. In addition,
the expression of the gene (CYP24A1) regulating the enzyme
involved in maintaining homeostatic levels of 1,25(OH)2D is
decreased by DNA methylation (Novakovic et al., 2009).
The human placenta expresses all of the metabolic
components associated with Vitamin D signaling, including
VDR, RXR, CYP27B1, CYP24A1, and CYP2R1 (Ma et al.,
2012). Vitamin D modulates implantation and placentation via
two mechanisms; it increases the expression of the homeobox
gene HOXA10 and increases the immune tolerance toward
the embryo. The increase in HOXA10 expression enhances
the endometrium’s responsiveness to the embryo and aids
implantation (Du et al., 2005). In the human syncytiotrophoblast,
Vitamin D and its components act together to enhance the
expressions of human chorionic gonadotropin (hCG), human
placental lactogen, estrogen and progesterone (Shin et al., 2010).
Expression levels of Vitamin D metabolic components also
change significantly during pregnancy (Kumar et al., 1979;
Paulson and Deluca, 1986). In the first- and second- trimester
of a normal human pregnancy, expression of CYP27B1 and
VDR is significantly increased over ten-fold in the placenta
and decidua compared with the endometrium (Fischer et al.,
2007; Novakovic et al., 2009). In particular, VDR is strongly
expressed across gestation in both the cytotrophoblast and
syncytiotrophoblast (Pospechova et al., 2009; Ma et al., 2012).
Notably, gene polymorphisms of VDR and its metabolites are
associated with several forms of cancer (including lung, breast,
colorectal, and prostate cancer), multiple sclerosis, chronic
obstructive pulmonary disease, and type I diabetes (Shin et al.,
2010). Some of these polymorphisms alter circulating levels of
25(OH)D and disrupt normal Vitamin D actions (McGrath et al.,
2010).
The expression of the metabolic components of Vitamin D,
including placental VDR, has been reported by many studies.
Zehnder et al. demonstrated that mRNA expression of 1α-
hydroxylase was found to be greater in the first and second
trimester than in third-trimester placentae, whereas the mRNA
expression of VDR was consistent and pronounced throughout
gestation (Zehnder et al., 2002). VDR is an essential component
of the Vitamin D metabolic pathway, whereupon activation
regulates and initiates the expression of numerous genes involved
in cell proliferation and differentiation (Samuel and Sitrin, 2008).
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Furthermore, VDR expression in the placenta is finely tuned
during pregnancy, indicating its eminent role in the development
of the placenta and the fetus (Shahbazi et al., 2011).
VITAMIN D DEFICIENCY IN FETAL
DEVELOPMENT
Birth cohort studies are an invaluable resource for studies of
the influence of the fetal environment on health in later life.
However, to what extent maternal vitamin D status influences
fetal development remains uncertain. In a recent study by Hart
et al. (2015) examined for the relationship between maternal
vitamin D deficiency at 18 weeks’ pregnancy and the long-
term health outcomes of offspring who were born in Perth,
Western Australia, in 1989–1991 by using a cohort of 901
mother-offspring pairs from the Western Australian Pregnancy
Cohort [Raine] Study (Hart et al., 2015). The authors reported
that Vitamin D deficiency as defined by the circulating serum
concentrations of [25(OH)D] <50 nmol/L was observed in
36% of the pregnant women included in this study. Maternal
Vitamin D deficiency during pregnancy was correlated with
the offspring’s development at various age groups for impaired
lung development, neurocognitive disorders, eating disorders in
adolescence, bone mass (Hart et al., 2015). This study concluded
that sufficient maternal Vitamin D is a critical factor during
fetal development in utero, more specifically for the optimal
development of multiple organ systems. These observations also
suggest that Vitamin D may have a pivotal, multifaceted role in
the development of fetal lungs, brain, and bone.
PLACENTAL VITAMIN D AND ITS
CONTRIBUTION TO FGR
We have recently demonstrated that placental vitamin D content,
as well as placental VDR expression, are decreased in human FGR
and contribute to trophoblast dysfunction (Nguyen et al., 2015a).
Therefore, decreased placental VDR expression may impair or
limit the beneficial actions and effects of maternal/placental
Vitamin D in the regulation of feto-placental growth. However,
our results did not clarify whether the changes associated with
placental VDR expression in FGR pregnancies are due to cause
or a consequence of the pathophysiological defects observed in
the FGR-affected placentae.
Genetic and epigenetic factors are known regulators of
Vitamin D and its metabolic components. Therefore, they
may have a significant influence on feto-placental development
(Sandovici et al., 2012). Previous studies have reported that
the placental Vitamin D metabolic components are tightly
regulated by epigenetic DNAmethylation (Novakovic et al., 2009;
Saffery et al., 2009) and hypermethylation of genes regulating
the VDR gene may contribute to the reduced placental VDR
observed FGR-affected pregnancies. Other potential causes for
the decreased VDR in FGRmay be due to polymorphism ofVDR,
which are known to affect the expression and function of VDR
(Jurutka et al., 2001; Whitfield et al., 2001). VDR polymorphisms
have been shown to modify the effect of maternal 25(OH)D on
offspring size (Morley et al., 2009).
Several in vitro studies have demonstrated that placental
Vitamin D and its receptor, VDR play critical roles in the
maintenance of normal cellular functions such as proliferation,
migration, differentiation and apoptosis. Decreased trophoblast
invasion, inadequate remodeling of uterine arterioles (Kaufmann
et al., 2003), reduced cytotrophoblast proliferation (Chen
et al., 2002), increased cytotrophoblast apoptosis (Crocker
et al., 2003), and fusion (Newhouse et al., 2007) are associated
with placental insufficiency, which is a key characteristic
of FGR pregnancies. Additionally, FGR is characterized
by impaired villous trophoblast fusion forming the multi-
nucleated syncytiotrophoblast (Kaufmann et al., 2003; Huppertz
and Kingdom, 2004; Newhouse et al., 2007). Therefore,
decreased placental expression of VDR in the placenta may be a
contributing factor to the pathology of idiopathic FGR-affected
pregnancies.
BeWo cells, a human choriocarcinoma-derived cell line that
is a well-established model for the syncytiotrophoblast, have
previously been shown to produce differentiating markers after
undergoing syncytialization in the presence of forskolin (an
agent increasing cAMP levels) (Mi et al., 2000; Vargas et al.,
2008). Pronounced syncytin expression is followed by further
cellular differentiation and generation of the syncytium as well
as the formation of gap junctions with an associated increase
in β-hCG secretion (Frendo et al., 2003; Pathirage et al.,
2013). Furthermore, trophoblast syncytialisation is associated
with decreased CYP27B1 in vitro, (Avila et al., 2004). Previous
studies using BeWo cells as a model for syncytiotrophoblast
has demonstrated that VDR is a critical regulator of pregnancy
and placental hormone secretion including placental lactogen
expression and β-hCG (Tuan et al., 1991; Stephanou et al., 1994;
Barrera et al., 2008).
In a recent study from our laboratory, we have further
confirmed that VDR is involved in BeWo cell differentiation,
when treated with a chemical inducer of fusion called forskolin.
Differentiation potential of BeWo was evidenced by an increase
in β-hCG, which may be due to direct or indirect regulatory
role of VDR on β-hCG expression (Nguyen et al., 2015a). In
the same study, we have also demonstrated that when VDR
mRNA was reduced following siRNA treatment, an increased
syncytium formation was observed compared to cells that were
treated with non-targeted siRNA control. These observations
suggested that VDR inactivation influenced larger syncytium
formation in vitro. Our study further demonstrated that reduced
VDR in these BeWo cells also significantly increased apoptosis,
when measured using TP53 mRNA as a marker of apoptosis.
Together our own studies suggested the decreased placental VDR
may contribute to the increased apoptosis associated with FGR
pathogenesis. Alterations in the rate of placental trophoblast and
endothelial cell proliferation, differentiation and apoptosis are
involved in the pathogenesis of FGR. VDRmay confer protection
against extrinsic apoptosis and contribute to the maintenance of
trophoblast function under adverse conditions, such as chronic
hypoxia, inflammation, and under-nutrition, all of which have
been linked to FGR. Thus, VDR is likely to be an important
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FIGURE 1 | Placental VDR expression and its contribution to the
pathogenesis of FGR.
regulator of placental functional sufficiency, which is vital for a
healthy fetal outcome. However, further studies are warranted
to understand the precise cellular and molecular mechanisms by
which VDR may contribute to FGR pathogenesis.
DOWNSTREAM TARGETS OF VDR IN THE
PLACENTA
Feto-placental growth is a complex cascade process requiring
tight regulation of cell cycle gene expressions at the
transcriptional level. Proliferation, continuous syncytial
fusion and a cascade of apoptosis are necessary for the integrity
and maintenance of the syncytium layer (Huppertz et al., 1998),
and for the remodeling of spiral arterioles by migratory and
invasive extravillous cytotrophoblats (EVCTs) (Lyall et al., 1999).
Trophoblast proliferation is regulated spatially and temporally
throughout pregnancy (Morrish et al., 1998). Proliferation or cell
division goes through cell growth and DNA synthesis phases,
which are mediated by checkpoints to ensure the cell’s fidelity.
In our most recent study, (Nguyen et al., 2015b), we identified
TGFβ-3, a known inhibitor of cell cycle progression through G1
phase (Caniggia et al., 1999), as a candidate downstream target
gene of VDR. Indeed, TGFβ-3 mRNA and protein expression
were significantly decreased in placentae from idiopathic
FGR-affected pregnancies compared to control placentae.
Decreased TGFβ-3 may contribute to inhibition of the G1 phase
of a cell cycle resulting in uncontrolled cell proliferation and
premature differentiation of cytotrophoblasts, thereby leading to
impaired ion and nutrient exchange, and decreased synthesis of
hormones required for feto-placental growth and development.
Thus, decreased TGFβ-3 caused by changes in VDR signaling
may directly or indirectly contribute to placental insufficiency,
which is a characteristic of human idiopathic FGR.
As depicted in Figure 1, decreased VDR expression in
placentae from FGR pregnancies contribute to alterations in the
rate of trophoblast proliferation, differentiation and apoptosis,
which are the key features of FGR pathogenesis (Nguyen et al.,
2015a). Thus, placental VDR is a critical regulator of feto-
placental growth.
CLINICAL SIGNIFICANCE AND FUTURE
DIRECTIONS
If perturbations of placental Vitamin D metabolism, such as
decreased placental Vitamin D synthesis and VDR expression,
do indeed contribute to FGR, then FGR might be treatable or
even prevented through maternal Vitamin D supplementation
early in pregnancy. The efficacy of maternally administered
Vitamin D supplements should obviously be evaluated more
thoroughly, but potentially new intervention strategies that target
the placenta might prevent or alleviate altered fetal growth
by improving placental Vitamin D metabolism, and thereby
improve placental growth and function. Further elucidation
of the biological mechanisms by which placental Vitamin D
metabolism contribute to FGR will not only increase our
understanding of the molecular mechanisms underlying FGR,
but may also provide novel approaches to intervention.
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